These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 22907938)
1. Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawal. Daelman L; Maitrot A; Maarouf A; Chaunu MP; Papeix C; Tourbah A Mult Scler; 2012 Nov; 18(11):1647-9. PubMed ID: 22907938 [TBL] [Abstract][Full Text] [Related]
2. Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findings. Rinaldi F; Seppi D; Calabrese M; Perini P; Gallo P Mult Scler; 2012 Nov; 18(11):1640-3. PubMed ID: 23100526 [TBL] [Abstract][Full Text] [Related]
3. Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod. Jander S; Turowski B; Kieseier BC; Hartung HP Mult Scler; 2012 Nov; 18(11):1650-2. PubMed ID: 23100527 [TBL] [Abstract][Full Text] [Related]
4. Withdrawal of fingolimod treatment for relapsing-remitting multiple sclerosis: report of six cases. Hakiki B; Portaccio E; Giannini M; Razzolini L; Pastò L; Amato MP Mult Scler; 2012 Nov; 18(11):1636-9. PubMed ID: 22829326 [TBL] [Abstract][Full Text] [Related]
5. Early switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruption. Laroni A; Brogi D; Milesi V; Abate L; Uccelli A; Mancardi G Mult Scler; 2013 Aug; 19(9):1236-7. PubMed ID: 23184503 [No Abstract] [Full Text] [Related]
6. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis. Kalincik T; Horakova D; Spelman T; Jokubaitis V; Trojano M; Lugaresi A; Izquierdo G; Rozsa C; Grammond P; Alroughani R; Duquette P; Girard M; Pucci E; Lechner-Scott J; Slee M; Fernandez-Bolanos R; Grand'Maison F; Hupperts R; Verheul F; Hodgkinson S; Oreja-Guevara C; Spitaleri D; Barnett M; Terzi M; Bergamaschi R; McCombe P; Sanchez-Menoyo J; Simo M; Csepany T; Rum G; Boz C; Havrdova E; Butzkueven H; Ann Neurol; 2015 Mar; 77(3):425-35. PubMed ID: 25546031 [TBL] [Abstract][Full Text] [Related]
7. Switching from natalizumab to fingolimod: an observational study. Sempere AP; Martín-Medina P; Berenguer-Ruiz L; Pérez-Carmona N; Sanchez-Perez R; Polache-Vengud J; Feliu-Rey E Acta Neurol Scand; 2013 Aug; 128(2):e6-e10. PubMed ID: 23336398 [TBL] [Abstract][Full Text] [Related]
8. Are natalizumab and fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study. Gajofatto A; Bianchi MR; Deotto L; Benedetti MD Eur Neurol; 2014; 72(3-4):173-80. PubMed ID: 25226868 [TBL] [Abstract][Full Text] [Related]
9. Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis. Havla J; Tackenberg B; Hellwig K; Meinl I; Krumbholz M; Seitz F; Eienbröker C; Gold R; Hohlfeld R; Kleiter I; Kümpfel T J Neurol; 2013 May; 260(5):1382-7. PubMed ID: 23266894 [TBL] [Abstract][Full Text] [Related]
10. Previous treatment influences fingolimod efficacy in relapsing-remitting multiple sclerosis: results from an observational study. Baldi E; Guareschi A; Vitetta F; Senesi C; Curti E; Montepietra S; Simone AM; Immovilli P; Caniatti L; Tola MR; Pesci I; Montanari E; Sola P; Granella F; Motti L; Ferraro D Curr Med Res Opin; 2014 Sep; 30(9):1849-55. PubMed ID: 24831186 [TBL] [Abstract][Full Text] [Related]
11. Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS. Kappos L; Radue EW; Comi G; Montalban X; Butzkueven H; Wiendl H; Giovannoni G; Hartung HP; Derfuss T; Naegelin Y; Sprenger T; Mueller-Lenke N; Griffiths S; von Rosenstiel P; Gottschalk R; Zhang Y; Dahlke F; Tomic D; Neurology; 2015 Jul; 85(1):29-39. PubMed ID: 26024899 [TBL] [Abstract][Full Text] [Related]
12. Natalizumab to fingolimod: Questions answered, unanswered, and unasked. Stüve O; Bourdette D Neurology; 2015 Jul; 85(1):14-5. PubMed ID: 26024898 [No Abstract] [Full Text] [Related]
13. Time to talk about timing--when to start, stop and change anti-migratory drugs in MS. Stüve O; Hemmer B Mult Scler; 2012 Nov; 18(11):1514-6. PubMed ID: 23100520 [No Abstract] [Full Text] [Related]
14. Fingolimod to treat severe multiple sclerosis after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option? Maillart E; Louapre C; Lubetzki C; Papeix C Mult Scler; 2014 Apr; 20(4):505-9. PubMed ID: 24367037 [TBL] [Abstract][Full Text] [Related]
15. Predictors for multiple sclerosis relapses after switching from natalizumab to fingolimod. Hoepner R; Havla J; Eienbröker C; Tackenberg B; Hellwig K; Meinl I; Hohlfeld R; Gold R; Kümpfel T; Kleiter I Mult Scler; 2014 Nov; 20(13):1714-20. PubMed ID: 24842961 [TBL] [Abstract][Full Text] [Related]
16. Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment. Havla JB; Pellkofer HL; Meinl I; Gerdes LA; Hohlfeld R; Kümpfel T Arch Neurol; 2012 Feb; 69(2):262-4. PubMed ID: 22332194 [TBL] [Abstract][Full Text] [Related]
17. Severe disease reactivation in four patients with relapsing-remitting multiple sclerosis after fingolimod cessation. Berger B; Baumgartner A; Rauer S; Mader I; Luetzen N; Farenkopf U; Stich O J Neuroimmunol; 2015 May; 282():118-22. PubMed ID: 25903738 [TBL] [Abstract][Full Text] [Related]
19. Cost-minimization analysis of fingolimod compared with natalizumab for the treatment of relapsing-remitting multiple sclerosis in Sweden. Bergvall N; Tambour M; Henriksson F; Fredrikson S J Med Econ; 2013; 16(3):349-57. PubMed ID: 23211038 [TBL] [Abstract][Full Text] [Related]
20. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. Kappos L; Radue EW; O'Connor P; Polman C; Hohlfeld R; Calabresi P; Selmaj K; Agoropoulou C; Leyk M; Zhang-Auberson L; Burtin P; N Engl J Med; 2010 Feb; 362(5):387-401. PubMed ID: 20089952 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]